Edition:
India

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

18.02USD
2:29am IST
Change (% chg)

$-1.55 (-7.92%)
Prev Close
$19.57
Open
$19.75
Day's High
$19.79
Day's Low
$17.93
Volume
1,085,931
Avg. Vol
835,187
52-wk High
$25.31
52-wk Low
$15.06

Latest Key Developments (Source: Significant Developments)

Exelixis Announces Results For Combination Of Cabozantinib And Nivolumab In Advanced Hepatocellular Carcinoma
Friday, 24 Jan 2020 

Jan 24 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES RESULTS FOR COMBINATION OF CABOZANTINIB AND NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA.EXELIXIS ANNOUNCES RESULTS FOR COMBINATION OF CABOZANTINIB AND NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA.EXELIXIS - NO NEW SAFETY SIGNALS WERE IDENTIFIED FOR COMBINATION OF CABOZANTINIB & NIVOLUMAB WITH OR WITHOUT IPILIMUMAB.EXELIXIS INC - TREATMENT-RELATED GRADE 3 OR 4 ADVERSE EVENTS WERE OBSERVED IN 47% OF CABOZANTINIB AND NIVOLUMAB GROUP.EXELIXIS - TREATMENT-RELATED GRADE 3 OR 4 ADVERSE EVENTS WERE OBSERVED IN 71% OF CABOZANTINIB, NIVOLUMAB AND IPILIMUMAB GROUP.  Full Article

Exelixis Outlines Key Priorities And Anticipated Milestones For 2020-21, Provides 2020 Financial Guidance
Monday, 13 Jan 2020 

Jan 12 (Reuters) - Exelixis Inc ::EXELIXIS OUTLINES KEY PRIORITIES AND ANTICIPATED MILESTONES FOR 2020-21, ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, AND PROVIDES 2020 FINANCIAL GUIDANCE.SEES FY 2020 REVENUE $850 MILLION TO $900 MILLION.TOTAL REVENUES ARE EXPECTED TO BE BETWEEN $850 MILLION AND $900 MILLION FOR 2020.RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE BETWEEN $460 MILLION AND $500 MILLION FOR 2020.CASH AND INVESTMENTS AT YEAR END 2020 ARE EXPECTED TO BE IN $1.5 BILLION TO $1.6 BILLION RANGE.TOTAL REVENUES FOR 2019 ARE APPROXIMATELY $972 MILLION FOR FULL YEAR AND APPROXIMATELY $245 MILLION FOR Q4 2019.RESEARCH AND DEVELOPMENT EXPENSES FOR 2019 ARE APPROXIMATELY $340 MILLION FOR FULL YEAR AND APPROXIMATELY $98 MILLION FOR Q4 2019.  Full Article

Exelixis Says Received A Paragraph IV Certification Notice Letter From MSN Pharma
Tuesday, 8 Oct 2019 

Oct 7 (Reuters) - Exelixis Inc ::EXELIXIS INC - RECEIVED A PARAGRAPH IV CERTIFICATION NOTICE LETTER FROM MSN PHARMACEUTICALS.EXELIXIS INC - MSN FILED AN ANDA WITH U.S. FDA FOR A GENERIC VERSION OF CABOMETYX TABLETS.EXELIXIS INC - NOTICE STATES THAT MSN INTENDS TO MARKET A GENERIC VERSION OF CABOMETYX.EXELIXIS INC - NOTICE ALLEGES THAT SUBJECT PATENTS ARE INVALID.EXELIXIS INC - CURRENTLY IS REVIEWING NOTICE.  Full Article

Exelixis Q1 GAAP Earnings Per Share $0.24
Thursday, 2 May 2019 

May 1 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 NON-GAAP EARNINGS PER SHARE $0.27.Q1 GAAP EARNINGS PER SHARE $0.24.Q1 REVENUE $215.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $212.2 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.23 -- REFINITIV IBES DATA.MAINTAINING FOLLOWING FINANCIAL GUIDANCE FOR 2019.  Full Article

Exelixis' Partner Takeda Announces Filing Of NDA In Japan For Cabometyx For Advanced Renal Cell Carcinoma
Thursday, 25 Apr 2019 

April 25 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER TAKEDA ANNOUNCES FILING OF NEW DRUG APPLICATION IN JAPAN FOR CABOMETYX® (CABOZANTINIB) FOR ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - REGULATORY SUBMISSION TRIGGERS $10 MILLION MILESTONE PAYMENT TO EXELIXIS UNDER COLLABORATION AND LICENSE AGREEMENT WITH TAKEDA.EXELIXIS INC - EXELIXIS WILL RECEIVE A $10 MILLION MILESTONE PAYMENT FROM TAKEDA, ANTICIPATED TO BE RECEIVED IN Q2 OF 2019.EXELIXIS INC - SUBMISSION BASED ON METEOR AND CABOSUN TRIALS AS WELL AS TAKEDA BRIDGING STUDY.  Full Article

Exelixis Announces U.S. FDA Approval Of Cabometyx Tablets For Previously Treated Hepatocellular Carcinoma
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA.EXELIXIS INC - APPROVAL BASED ON CELESTIAL PHASE 3 PIVOTAL TRIAL.  Full Article

Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For Minnebro Tablets In Japan
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS’ COLLABORATOR DAIICHI SANKYO RECEIVES REGULATORY APPROVAL FOR MINNEBRO™ (ESAXERENONE) TABLETS FOR THE TREATMENT OF HYPERTENSION IN JAPAN.EXELIXIS INC - APPROVAL ALLOWS FOR MARKETING OF MINNEBRO FOR THE INDICATION WITHIN JAPAN..  Full Article

Exelixis Reports Q2 Earnings Per Share $0.28
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 EARNINGS PER SHARE $0.28.Q2 REVENUE $186.1 MILLION VERSUS I/B/E/S VIEW $155.9 MILLION.Q2 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S.MAINTAINING ITS GUIDANCE THAT TOTAL COSTS AND OPERATING EXPENSES FOR FULL YEAR WILL BE BETWEEN $430 MILLION AND $460 MILLION.  Full Article

Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib
Thursday, 10 May 2018 

May 10 (Reuters) - Exelixis Inc ::EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL VERSUS REGORAFENIB.GENENTECH INFORMED CO COMBINATION OF ATEZOLIZUMAB AND COBIMETINIB DID NOT DELIVER IMPROVEMENT IN OVERALL SURVIVAL VERSUS REGORAFENIB.GENENTECH WILL FURTHER EXAMINE RESULTS FROM IMBLAZE370 AND PLANS TO PRESENT DATA AT AN UPCOMING MEDICAL MEETING.  Full Article